Médecine Nucléaire, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Interdisciplinary cancer research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Hematology Reports, Год журнала: 2025, Номер 17(3), С. 23 - 23
Опубликована: Апрель 28, 2025
Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare and aggressive non-Hodgkin (NHL), considered specific entity with proper characteristics, therapies, prognosis. First-line treatment not unique, subsequent strategies in case of disease persistence or relapse are the subject debate studies. In this scenario, [18F]FDG PET/CT plays pivotal role both characterizing mass, main feature PMLBCL, staging, restaging during therapy (interim PET), at end (EoT to guide clinical management give prognostic insights. The issue PMLBCL distinguishing viable from residual fibrotic/inflammatory mass after and, consequently, settling next strategy. Novel therapeutic approaches ongoing associated deepening potentials as principal tool context. review, we will explore Nuclear Medicine point view help clinicians these patients.
Язык: Английский
Процитировано
0
The Journal of Infectious Diseases, Год журнала: 2024, Номер 231(2), С. 532 - 539
Опубликована: Авг. 15, 2024
The role of 2-deoxy-2-18(F) fluoro-D-glucose (FDG) positron emission tomography (PET)-computed (CT) in assessing treatment response chronic pulmonary aspergillosis (CPA) remains to be determined. study objective was compare FDG-PET/CT parameters persons with CPA achieving success or failure after 6 months oral itraconazole. We performed PET-CT at baseline and itraconazole therapy. FDG uptake similar the background ≥13 units decline Z-score considered a complete metabolic (CMR). A >25%, >30%, > 45% standardised value (SUVmax), SUVpeak, total glycolytic activity (TLG) labelled as partial (PMR). >75% increase SUVmax, TLG represented progressive disease. included 94 (63 male) mean age 46.2 years. follow-up on 77 participants. recorded 43 34 patients. CMR seen 18.6% those none failure. higher proportion patients achieved PMR; 19% had Most improved treatment; however, misclassified one-fifth
Язык: Английский
Процитировано
3
Clinical and Translational Imaging, Год журнала: 2023, Номер 12(1), С. 99 - 107
Опубликована: Авг. 26, 2023
Abstract Introduction The present web-based national survey aims to assess the clinician's perspective toward (1) indications perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) utility of interaction with referring nuclear medicine physician, and (3) their perception clarity, usefulness, impact PET/CT report. Methods We conducted a prospective consisting 31 multiple-choice questions an open-text field. questionnaire was administered Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams values expressed as numbers (percentages). Results A total 373 physicians completed questionnaire. Among 360 responses finally included analysis, majority came from radiation oncologists (46%), followed by oncologists. For half respondents (53%), examination “often” clear easily accessible, but only 16% considered them “absolutely” accessible. Additionally, most (43%) necessary facilitate access update. physician generally useful satisfying. Regarding report, 74% standardize report structure, presence semi-quantitative parameters great importance. Finally, about cases impacts patient management major changes. Conclusion To sum up, “still not” complete confidence need update emerged our results. Moreover, structured clarification on essential PET features is warranted. In this scenario, participation guideline committees, international conferences well continuous training among all specialists involved patients’ could be effective strategies resolve clinicians' concerns PET/CT, thereby improving
Язык: Английский
Процитировано
3
European Journal of Theoretical and Applied Sciences, Год журнала: 2024, Номер 2(1), С. 623 - 633
Опубликована: Янв. 1, 2024
Positron Emission Tomography/Computed Tomography (PET/CT)-guided radiation therapy simulation has transformed cancer treatment, ushering in enhanced precision and individualization. This discussion delves into clinical indications, applications, procedures, limitations, providing a comprehensive overview across types. Clinical indications underscore PET/CT's role accurate staging, target volume delineation, treatment response assessment, post-treatment recurrence detection. Accurate staging is crucial for tailored plans, while delineation benefits from PET's identification of metabolic patterns. Ongoing assessment enables dynamic adjustments, post-treatment, PET/CT aids detecting recurrent disease. Applications highlight planning optimization by combining anatomical functional information. Fusion PET CT images customizes identifying active regions targeted delivery sparing healthy tissues. fusion facilitates strategies, minimizing exposure enabling adaptations. Procedural aspects detail imaging acquisition, image fusion, planning, ongoing monitoring. Starting with radiotracer administration, typically fluorodeoxyglucose (FDG), captures data. Image optimizing plans. monitoring allows real-time adjustments. Specific applications cancers demonstrate versatility. In head neck cancers, it ensures precise avoiding critical structures. lung cancer, improves tumor extent identification. Similar advantages apply to lymphomas, sarcomas, brain tumors, metastatic disease, esophageal, gastrointestinal, breast, prostate, gynecological, pediatric cancers. Limitations include spatial resolution challenges, false positives, cumulative exposure, lesion size, histology, standardization issues. research targets enhancement, radiomics AI integration, novel tracers, hybrid imaging, patient-specific dosimetry, trials, multimodal workflows, cost-effectiveness, accessibility, education. PET/CT-guided transformative. advancements promise more individualized approach, enhancing patient outcomes management.
Язык: Английский
Процитировано
0
Medical Sciences, Год журнала: 2024, Номер 12(3), С. 36 - 36
Опубликована: Июль 29, 2024
Background: The prognostic role of imaging with [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) in oropharynx cancer (OPC) has been demonstrated the past. aim this study was to assess impact both baseline and post-treatment PET/CT patients OPC treated chemo- and/or radiotherapy. Methods: parameters scans performed before after therapy were collected analyzed find significant prognosticators for progression-free survival (PFS) overall (OS). Human papillomavirus (HPV) infection’s influence on prognosis also taken into account. Results: A total 66 included study. staging volumetric OS, while same affordable predictors PFS at restaging evaluation. No correlations between HPV infection reported. Conclusion: [18F]FDG
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2024, Номер 16(16), С. 2900 - 2900
Опубликована: Авг. 21, 2024
Introduction: There is growing interest in the development and application of standardized imaging criteria (SIC), to minimize variability improve reproducibility image interpretation head neck squamous cell carcinoma (HNSCC). Methods: “Squamous carcinoma” AND “standardized criteria” OR “radiographic response assessment” were searched using PubMed Google Scholar for articles published between 2009 2024, returning 56 publications. After abstract review, 18 selected further evaluation, 6 different SICs (i.e., PERCIST, Porceddu, Hopkins, NI-RADS, modified Deauville, Cuneo) included this review. Each SIC evaluated context 8 desired traits a reporting system. Results: Two have societal endorsements NI-RADS); four can be used evaluation locoregional systemic disease Cuneo), specific categories equivocal results Cuneo). All demonstrated areas future improvement traits. Conclusion: Multiple been developed value HNSCC post-treatment imaging; however, these systems remain underutilized. Selecting an with features that best match needs one’s practice expected maximize likelihood successful implementation.
Язык: Английский
Процитировано
0
Médecine Nucléaire, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Процитировано
0